Lumicitabine - Alios BioPharma/Janssen
Alternative Names: AL 8176; ALS 008176; ALS-8176; JNJ-1575; JNJ-64041575Latest Information Update: 23 Mar 2023
At a glance
- Originator Alios BioPharma
- Developer Alios BioPharma; Janssen Research & Development
- Class Antivirals; Esters; Furans; Nucleosides; Pyrimidines
- Mechanism of Action RNA replicase inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Respiratory syncytial virus infections
- Discontinued Metapneumovirus infections; Parainfluenza virus infections
Most Recent Events
- 23 Mar 2023 Discontinued - Preclinical for Metapneumovirus infections in USA (PO)
- 23 Mar 2023 Discontinued - Preclinical for Parainfluenza virus infections in USA (PO)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Metapneumovirus-infections in USA (PO)